Menu
Search
|

Menu

Close
X

Roche Holding AG RO.S (Swiss Exchange)

250.00 CHF
+3.60 (+1.46%)
As of Nov 16
chart
Previous Close 246.40
Open 249.20
Volume 23,896
3m Avg Volume 26,131
Today’s High 250.60
Today’s Low 247.80
52 Week High 255.00
52 Week Low 209.40
Shares Outstanding (mil) 862.56
Market Capitalization (mil) 214,033.70
Forward P/E 22.03
Dividend (Yield %) 8.20 ( 3.31 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 27 analysts

KEY STATS

Revenue (mm, CHF)
FY18
28,111
FY17
53,299
FY16
50,576
FY15
48,145
EPS (CHF)
FY18
8.508
FY17
10.037
FY16
11.132
FY15
10.281
*Note: Units in Millions of Swiss Francs
**Note: Units in Swiss Francs

KEY RATIOS

Price to Earnings (TTM)
vs sector
22.03
33.59
Price to Sales (TTM)
vs sector
4.12
5.69
Price to Book (MRQ)
vs sector
9.27
5.11
Price to Cash Flow (TTM)
vs sector
15.49
23.52
Total Debt to Equity (MRQ)
vs sector
92.54
15.71
LT Debt to Equity (MRQ)
vs sector
73.33
11.53
Return on Investment (TTM)
vs sector
20.46
15.05
Return on Equity (TTM)
vs sector
46.88
16.62

EXECUTIVE LEADERSHIP

Severin Schwan
Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director, Since 2013
Salary: CHF4,000,000.00
Bonus: CHF2,791,950.00
Christoph Franz
Non-Executive Chairman of the Board, Since 2011
Salary: CHF3,500,000.00
Bonus: CHF558,390.00
Fritz Gerber
Honorary Chairman of the Board, Since 2004
Salary: --
Bonus: --
Andre Hoffmann
Non-Executive Vice Chairman of the Board, Since
Salary: CHF400,000.00
Bonus: --
Alan Hippe
Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer, Since 2011
Salary: CHF1,600,000.00
Bonus: CHF2,000,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Grenzacherstr. 124
BASEL     4058

Phone: +419.732354295

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

SPONSORED STORIES